Notice of Results

 

TIDMGWP 
 
RNS Number : 8471Q 
GW Pharmaceuticals PLC 
20 April 2009 
 

GW Pharmaceuticals plc 
 
 
 
 
Notification of Results 
 
 
Porton Down, UK, 20 April, 2009: GW Pharmaceuticals plc (AIM: GWP) will be 
announcing its interim financial results for the six months ended 31 March 2009 
on Wednesday 20 May 2009. 
 
 
 
 
Enquiries: 
 
 
+--------------------------------------+---------------------+ 
| Financial Dynamics                   | 020 7831 3113       | 
+--------------------------------------+---------------------+ 
| Ben Atwell / John Dineen             |                     | 
+--------------------------------------+---------------------+ 
 
 
 
 
 
 
Notes to Editors 
 
 
About GW Pharmaceuticals 
GW was founded in 1998 and listed on the AIM, a market of the London Stock 
Exchange in June 2001. Operating under license from the UK Home Office, the 
company is developing cannabis-derived pharmaceutical products for patients with 
multiple sclerosis, neuropathic pain, cancer pain, spinal cord injury, 
rheumatoid arthritis, and other severe medical conditions. 
 
 
GW has assembled a team of over 100 scientists with extensive experience in 
developing both plant-based prescription pharmaceutical products and medicines 
containing controlled substances. GW is dedicated to developing treatment 
options that alleviate pain symptoms in patients who suffer from serious 
ailments. 
 
 
For further information, please visit the Company's website: www.gwpharm.com 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 NORZBLFLKZBLBBB